Compare HZO & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HZO | ABUS |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 788.1M | 839.5M |
| IPO Year | 1998 | 2008 |
| Metric | HZO | ABUS |
|---|---|---|
| Price | $52.11 | $5.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $30.00 | $5.00 |
| AVG Volume (30 Days) | 815.8K | ★ 2.1M |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | 0.21 | ★ 0.84 |
| Revenue | ★ $2,309,288,000.00 | $14,083,000.00 |
| Revenue This Year | $3.67 | N/A |
| Revenue Next Year | $4.01 | $239.71 |
| P/E Ratio | $248.57 | ★ $6.19 |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $21.42 | $3.50 |
| 52 Week High | $52.46 | $5.45 |
| Indicator | HZO | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 81.04 | 66.79 |
| Support Level | $31.96 | $4.15 |
| Resistance Level | $52.46 | $5.38 |
| Average True Range (ATR) | 0.60 | 0.19 |
| MACD | 0.54 | 0.07 |
| Stochastic Oscillator | 98.26 | 74.76 |
MarineMax Inc is a United-States-based company that sells new and used recreational boats under premium brands, and related marine products, like engines, parts, and accessories. The company is also engaged in other businesses, including providing services of repair, maintenance, and storage; managing related boat financing, insurance, and others; offering brokerage sales of boats and yachts; and operating a yacht charter business. The reportable segments of the company are Retail Operations and Product Manufacturing. The Retail Operations segment generates the majority of the company's revenue. The sale of new and used boats accounts for the majority of the company's total revenue. It serves customers across the U.S and international market.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.